University Of Iowa Research Foundation

UIRF Ref. No: 03036

METHODS AND COMPOSITIONS FOR DEGRADATION OF NITROAROMATIC AND NITRAMINE POLLUTANTS

TECHNOLOGY REVIEW

The invention describes a novel strain of bacteria, and methods and kits for using it to degrade a variety of Nitroaromatic, Nitramine and other pollutants. These pollutants are frequently generated in the production of explosives, such as TNT (2,4,6-trinotrotoluene), RDX (Royal demolition explosive; hexahydro-1,3,5-trinitro-1,3,5-triazine) and HMX (High melting point explosive; octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine). Nitroaromatic and nitramine compounds comprise a class of pollutants known to have both toxic and carcinogenic properties.

The invention describes methods of use including the distribution of the bacterium and other bacterium in the genus over areas of soil, fresh water or sediment in order for the conversion of the nitroaromatic or nitramine compounds to a form that has reduced toxicity and/or are fully degraded (i.e., mineralized).

INVENTORS

Jerald Schnoor and Benoit Van Aken

INTELLECTUAL PROPERTY STATUS

Granted U.S. Patent No. 7,214,509; U.S. Patent Application Pending

CONTACT INFORMATION

UIRF Ref. No: 06063

Compounds Offering Protection Against Gastrointestinal Pathogens

TECH FIELDS

Pharmaceuticals - Neonatal
Health - Nutraceuticals

FEATURES

• Discovery of a novel use for a known, readily available compound
• Prevents and treats patient populations at risk of developing systemic infection from the gastrointestinal tract such as newborns, cancer patients or critically ill patients in an ICU
• Can be administered using milk or water as a carrier
• May be used to supplement breast milk or to optimize infant formula or other infant food
• Likely one of the immunoprotective compounds in breast milk

BENEFITS

• Prevents neonatal gastrointestinal infections and sepsis, common in premature infants, as well as other patient populations
• Not an antibiotic so no risk of contributing to the production of antibiotic resistant bacteria

TECHNOLOGY REVIEW

In animal studies, surfactant-associated proteins produced by newborns or their mothers conferred protection against neonatal necrotizing enterocolitis, and the associated morbidity and mortality. Mice lacking the surfactant-associated protein A (SP-A) gene, deliver similarly to normal mothers, however, newborns of the SP-A null mothers died at a higher rate when exposed to environmental bacteria. Surfactant-Associated Protein D (SP-D) mRNA and protein are produced in the lactating mammary gland but are not present in non-lactating mammary tissue. SP-D is present in milk.

INVENTORS

Caroline George, Jeanne Snyder, Fred Lamb

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 83007

CMV PROMOTER FOR INCREASED EXPRESSION

TECHNOLOGY REVIEW

Available for non-exclusive licensing by fields of use.

These patents describe the cloning and usefulness of a human cytomegalovirus (HCMV) immediate-early regulatory DNA sequence termed the CMV promoter, that functions in a variety of different cell types. This promoter has been shown to be capable of significantly increasing the expression of a wide variety of genes. These genes cover a broad eukaryotic host range, thus making the CMV promoter particularly useful for both recombinant protein production as well as gene therapy/genetic immunization protocols. These patents are being licensed non-exclusively by fields of use. License terms have currently been set for licenses executed before December 1, 2005. License terms are subject to change after this date.

INVENTORS

Mark F. Stinski, Professor, Department of Microbiology, University of Iowa

INTELLECTUAL PROPERTY STATUS

U.S. Patent Nos. 5,168,062 issued December 1, 1992 and 5,385,839 issued January 31, 1995.

CONTACT INFORMATION

UIRF Ref. No: 08006

METHODS AND COMPOSITIONS FOR TREATING BRAIN DISEASES

TECHNOLOGY REVIEW

Methods and compositions for targeting the brain microvascular endothelium. The invention includes proteins that function to target viral vectors to vascular endothelial cells of the nervous system.

The compositions described would be useful in targeting cancers of the brain, and Lysosomal Storage Diseases.

INVENTORS

Beverly Davidson, et al

INTELLECTUAL PROPERTY STATUS

Patent applications pending

CONTACT INFORMATION

UIRF Ref. No: 04024

METHODS FOR PRODUCING AND USING IN VIVO PSEUDOTYPED RETROVIRUSES USING ENVELOPE GLYCOPROTEINS FROM LYMPHOCYTIC CHORIOMENINGITIS VIRUS (LCMV)

TECHNOLOGY REVIEW

The present invention provides a retrovirus virion pseudotyped with a Lymphocytic Choriomeningitis Virus (LCMV) envelope glycoprotein. The invention also describes a pseudotyped feline immunodeficiency virus (FIV) virion comprising an envelope glycoprotein from LCMV. The invention provides a method to pseudotype retroviruses to attain high titers suitable for ex vivo and in vivo gene transfer. The invention will be useful for gene therapy applications using retroviral vectors and provide a novel method for increasing the transduction efficiency and the targeting of specific cell types that were previously poorly accessible. In particular these methods may have applications for targeting tissues such as airway epithelia, cells of the CNS, hepatocytes and others. The methods may also facilitate the production of stable packaging cell lines for vector production.
Relevant Publication: Stein CS, Martins I, Davidson BL.; The lymphocytic choriomeningitis virus envelope glycoprotein targets lentiviral gene transfer vector to neural progenitors in the murine brain. Mol Ther. 2005 Mar;11(3):382-9.

INVENTORS

Paul B. McCray, Jr. and Beverly L. Davidson

INTELLECTUAL PROPERTY STATUS

U.S. Patent 7,135,339 issued November 14, 2006
U.S. Patent 7,160,727 issued January 9, 2007

CONTACT INFORMATION

UIRF Ref. No: 04017

METHODS FOR PRODUCING AND USING IN VIVO PSEUDOTYPE D RETROVIRUSES

TECHNOLOGY REVIEW

The present invention provides a retrovirus virion pseudotyped with a baculovirus envelope glycoprotein. In one embodiment, the glycoprotein is glycoprotein-64 (GP64) derived from Autographa californica multinuclear polyhedrosis virus (AcMNPV). In another embodiment, the glycoprotein is glycoprotein-75 (GP75) from a type D influenzae virus. The present invention further provides a vector containing a nucleic acid encoding a baculovirus envelope glycoprotein, an envelope glycoprotein from a type D influenzae virus, an F protein from an insect virus, or a metaviridae envelope protein. The present invention also provides a packaging cell containing a nucleic acid encoding a pseudotyping envelope glycoprotein.

The invention provides a method to pseudotype retroviruses to attain high titers suitable for ex vivo and in vivo gene transfer. The invention will be useful for gene therapy applications using retroviral vectors and provide a novel method for increasing the transduction efficiency and the targeting of specific cell types that were previously poorly accessible. In particular these methods may have applications for targeting tissues such as airway epithelia, cells of the CNS, hepatocytes and others. The methods may also facilitate the production of stable packaging cell lines for vector production.

Relevant Publications: Sinn, P. L., Shah, A. J., Donovan, M. D., and McCray, P. B., Viscoelastic Gel Formulations Enhance Airway Epithelial Gene Transfer with Viral Vectors, Am J Respir Cell Mol Biol, 32, 404-410, 2005

Sinn, P. L., Burnight, E. R., Hickey, M. A., Blissard, G. W., and McCray, P. B., Persistent Gene Expression in Mouse Nasal Epithelia following Feline Immunodeficiency Virus-Based Vector Gene Transfer, J Virology, 79:20, 12818-12827, 2005

Kan, Y, Xie, L, Tran, D. T., Stein, C. S., Hickey, M., Davidson, B. L., McCray, P. B., Persistent expression of factor VIII in vivo following nonprimate Lentiviral gene transfer, Gene Therapy, 106:5, 1552-1558, 2005

INVENTORS

Paul B. McCray, Jr. and Beverly L. Davidson

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed and PCT Application Filed

CONTACT INFORMATION

UIRF Ref. No: 01023

ADENOVIRUS SEROTYPE 30 (Ad30)

TECHNOLOGY REVIEW

The present invention provides an adenovirus serotype 30 (Ad30) fiber amino acid sequence. The present invention also provides polynucleotides and expression vectors encoding an Ad30 fiber and viral particles and cells containing such expression vectors. The present invention further provides methods of treating genetic diseases or cancers in a mammal using the polynucleotides, polypeptides, expression vectors, viral particles and cells of the present invention to transduce cells lacking CAR, specifically a neuroprogenitor or stem cell.

The present invention describes a new adenovirus serotype 30 (Ad30) fiber amino acid sequence, which shows improved tropism to neurons and human endothelial cells. This application also provides polynucleotides and expression vectors encoding an Ad30 fiber and viral particles and cells containing such expression vectors. This new serotype is shown to have higher efficiency of transduction in both CNS (central nervous system) and HUVECs (human umbilical vein epithelial cells). Methods are provided of treating genetic diseases or cancers in a mammal using the polynucleotides, polypeptides, expression vectors, viral particles and cells of the present invention.

Relevant publication: Adenovirus serotype 30 fiber does not mediate transduction via the coxsackie-adenovirus receptor, Lane Law and Beverly Davidson, J Virology. 2002, 76(2), 656-61.

INVENTORS

Beverly Davidson and Lane Law

INTELLECTUAL PROPERTY STATUS

Patent 6,635,466 issued October 21, 2003
Additional U.S. Patent Applications Filed

CONTACT INFORMATION

UIRF Ref. No: 98076

METHODS AND COMPOSITIONS FOR INCREASING THE INFECTIVITY OF GENE TRANSFER VECTORS

TECHNOLOGY REVIEW

The invention includes methods and compositions for increasing viral vector infection of epithelial cells and increasing the susceptibility of target cells to gene transfer vectors for the purpose treating or inhibiting a variety of diseases. The invention provides methods for expressing a polypeptide in cells of epithelial tissues. Specific examples in the area of treating Cystic Fibrosis with the CTFR gene, as well as a variety of other diseases and conditions for which genetic therapy may be appropriate are described in the invention. In the case of Cystic Fibrosis, a method of increasing transport of chloride ions in airway epithelial tissue is described as well as a method for transducing epithelial cells with a viral vector comprising delivering to said epithelial cells a packaged viral vector and EGTA in a hypotonic solution.

Relevant Publications: Influence of cell polarity on retroviral-mediated gene transfer to differentiated human airway, Wang G., Davidson B.L., Melchert P., van Es H.H.G., Slepushkin V.A., Bodner M., Jolly D.J., and McCray P.B. Jr., J Virol, 1998, 72:9818-9826.

Feline immunodeficiency virus vectors persistently transduce non-dividing airway epithelia in vivo and correct the CF defect, Wang G., Slepushkin V.A., Zabner J., Keshavjee S., Johnston J.C., Sauter J.C., Sauter S.L., Jolly D.J., Dubensky T., Davidson B.L., and McCray P.B. Jr., J Clin. Invest, 1999 104:R55-R62.

Increasing epithelial junction permeability enhances gene transfer to airway epithelia in vivo, Wang G., Zabner J., Deering C., Launspach J., Shao J., Bodner M., Jolly D.J., Davidson B.L., McCray P.B. Jr., Am J Respir Cell Mol Biol, 2000, 22:129-138.

INVENTORS

Beverly L. Davidson, Paul McCray, Guoshun Wang, DouglasJolly, Mordechai Bodner and Steven Hermann

INTELLECTUAL PROPERTY STATUS

Patent 6,855,549 issued February 15, 2005

CONTACT INFORMATION

UIRF Ref. No: 99065

USE OF RECOMBINANT GENE DELIVERY VECTORS FOR TREATING OR PREVENTING LYSOSOMAL STORAGE DISORDERS

TECHNOLOGY REVIEW

The invention describes compositions and methods for treating, preventing or inhibiting diseases of the eye. The compositions consist of a variety of lentivirus and feline immunodeficiency vectors (FIV). The methods include the intravitreous administration of the composition vector, which would direct the expression of one or more polypeptides, proteins or enzymes, so that the retinal disease of the eye is treated or prevented. Some of the diseases for which these compositions and methods may be effective include macular degeneration, Glaucoma, Sly syndrome, Bardet-Biedl syndrome, Congenital amaurosis, Cone or cone-rod dystrophy, Retinitis pigmentosa, and diabetic retinopathy.

The invention also provides compositions and methods for treating, preventing or inhibiting diseases of the brain and central nervous system related to lysosomal storage disorders. A variety of gene delivery vectors and injection sites and methods are described for different diseases. Some of these diseases may include Battens disease, mucolipidosis type IV, mucopolysaccharidoses type VII, CLN2 deficiency, infantile cystinosis, Chediak-Higashi syndrome, spinal cerebellar ataxias, Huntingtons disease, Alzheimers disease, ALS, and Hermansky-Pudlak syndrome.

Relevant Publications: Functional Correction of Established Central Nervous System Deficits in an Animal Model of Lysosomal Storage Disease with Feline Immunodeficiency Virus-based Vectors, Andrew I. Brooks, Colleen S. Stein, Stephanie M. Hughes, Jason Heth, Paul M. McCray, Jr., Sybille L. Sauter, Julie C. Johnston, Deborah A. Cory-Slechta, Howard J. Federoff, and Beverly L. Davidson, PNAS, 2002, 99, 6216-6221.

Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors, J. M. Alisky, S. M. Hughes, Sybille L. Sauter, Douglas J. Jolly, Thomas W. Dubensky Jr, P. D. Staber, J. A. Chiorini, and Davidson BL, NeuroReport, 2000, 11(12):2669-2673.

INVENTORS

Beverly L. Davidson, Colleen Stein, Jason Heth, Thomas W. Dubensky, Jr., Douglas Jolly, and Sybille L. Sauter

INTELLECTUAL PROPERTY STATUS

Patent 6,730,297 May 4, 2004 and U.S. Patent 7,034,010 April 25, 2006

CONTACT INFORMATION

UIRF Ref. No: 05044

2, 4, 6-TRISUBSTITUTED PHENOLS HAVING ANESTHETIC PROPERTIES

TECHNOLOGY REVIEW

A new group of synthesized Propofol derivatives. The new compounds are shorter acting, for quicker anesthetic induction. The compounds have a more predictable duration of action and cause less pain upon injection.

INVENTORS

Max Baker

INTELLECTUAL PROPERTY STATUS

Patent applications pending

CONTACT INFORMATION

UIRF Ref. No: 05069

HYDROFLUOROALKYL PHENOLS HAVING ANESTHETIC PROPERTIES

TECHNOLOGY REVIEW

Alkyl phenols have a broad range of medicinal properties ranging from central nervous system (CNS) effects to antioxidant activities. The effects of alkyl phenols on the CNS are generally sedative in nature. This invention discloses hydrofluoroalkyl phenols that have effects on the central nervous system including anesthesia and sedation. Other potential effects include muscle relaxation, pulmonary smooth muscle relaxation, anti-spasticity, and inhibition of endocannabinoid catabolism. Substitution of alkylphenols with fluorine is believed to be advantageous because in some cases fluorine can improve chemical and metabolic stability of a compound, and can favorably affect the pharmacokinectics/pharmadynamics of small molecules.

The compounds disclosed in this invention are useful for inducing anesthesia and sedation in mammals. Furthermore, compound MB009 has a shorter duration than propofol and may be useful in clinical situations when it is desirable to use a more rapidly acting anesthetic.

INVENTORS

Max T. Baker

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 02035

THE USE OF MELATONIN FOR INDUCTION OF GENERAL ANESTHESIA

TECHNOLOGY REVIEW

This invention discloses a novel use of melatonin, or biologically active analogues of melatonin, for induction of general anesthesia. It is anticipated that the use of melatonin agonists for sedation and anesthesia will result in less post anesthetic discomfort. The invention provides compounds useful for general anesthesia that will have limited toxicity to patients and less of what is known as anesthesia hangover.

INVENTORS

Max T. Baker, Mohammed Naguib

INTELLECTUAL PROPERTY STATUS

U.S. Patent No. 6,638,966

CONTACT INFORMATION

UIRF Ref. No: 04003

MELATONIN ANALOG PRODRUG

TECHNOLOGY REVIEW

Melatonin exerts a broad range of beneficial effects including sleep promotion, sedation, anesthesia, anti-oxidation, and protection of organs to chemical, infectious and cardiovascular damage. Melatonin is a water-insoluble compound that cannot be administered to patients by injection using an aqueous vehicle. Melatonin also cannot be formulated into an organic solvent that is free of undesirable side effects, nor can it be formulated in oil-in-water emulsions due to its insolubility in oil.Z

This invention discloses compounds that are prodrugs to melatonin analogs and that are soluble in nontoxic solvents. A prodrug is a drug which is administered in a significantly less active form. Once administered, the prodrug is metabolized or degrades in the body to release the active substance. These disclosed compounds will exert the beneficial effects of melatonin and can be administered in high concentrations in aqueous vehicles. This invention thereby overcomes the poor solubility of melatonin and melatonin analogs in nontoxic formulations so that the melatonin related compounds can be administered intravenously in adequate doses.

INVENTORS

Max T. Baker and Mohammed Naguib

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 00072

MELATONIN FOR INDUCTION OF GENERAL ANESTHESIA

TECHNOLOGY REVIEW

Melatonin exerts a broad range of beneficial effects including sleep promotion, sedation, anesthesia, anti-oxidation, and protection of organs to chemical, infectious and cardiovascular damage. Melatonin is a water-insoluble compound that cannot be administered to patients by injection using an aqueous vehicle. Melatonin also cannot be formulated into an organic solvent that is free of undesirable side effects, nor can it be formulated in oil-in-water emulsions due to its insolubility in oil.
This invention has as its primary objective the development of pineal hormone melatonin (N-acetyl-5-methoxytryptamine) or its biologically active analogues as a general anesthetic which can be used without any significant anesthesia hangover.

Relevant Publications: Naguib M, Samarkandi AH. Premedication with melatonin: a double-blind, placebo-controlled comparison with midazolam. British Journal of Anesthesia, 1999:82 (6); 875 80.

INVENTORS

Mohammed Naguib

INTELLECTUAL PROPERTY STATUS

U.S. Patent No. 6,552,064

CONTACT INFORMATION

UIRF Ref. No: 02003

FLUORINATED ALKYL PHENOL COMPOUNDS AND THEIR USE AS MEDICINAL AGENTS

TECHNOLOGY REVIEW

Alkyl phenols, such as the widely used intravenous anesthetic propofol, have a broad range of medicinal properties ranging from central nervous system (CNS) effects (anesthesia, sedation, anti-nausea) to direct antioxidant activity. The response of the CNS to alkyl phenols is generally sedative in nature which is thought to be due the interaction of these compounds with inhibitory GABAA receptors. This invention discloses novel alkyl phenol compounds that are fluorine substituted on the alkyl side groups. If was found that some in this class of compounds exhibit greater effectiveness than propofol onGABA receptor and exhibit anesthetic effects of shorter duration than propofol when administered intravenously possibly due to improved pharmacokinetics. These compounds may also exhibit the other desirable properties of propofol such as antimigraine and bronchodilation effects; the latter if administered by inhalation. These compounds can be formulated in emulsions, polyermic micelles or cyclodextrins similar to propofol.

INVENTORS

Max T. Baker, Mohammed Naguib

INTELLECTUAL PROPERTY STATUS

US patent # 7,312,250, issued 12/25/07

CONTACT INFORMATION

UIRF Ref. No: 93026-1

DEUTERATED SEVOFLURANE AS AN INHALATION ANESTHETIC

TECHNOLOGY REVIEW

Sevoflurane is a desirable fluorocarbon anesthetic widely used in the U.S. It is nonpungent and has a fast onset and offset of action. However, it is metabolized in the body to release considerable amounts of fluoride, a potential kidney toxin, and other metabolites that may affect the liver. This invention discloses a deuterated form of sevoflurane (fluoro-dideutero-methyl 1,1,1,3,3,3-hexafluoroisopropyl ether) and methods for its synthesis. Deuterated sevoflurane is a fast, non-pungent, easy-to-vaporize, non-blood pressure dropping, nonflammable anesthetic that does not poise a fluoride threat to the kidneys, nor a metabolism-based threat to other organs. Deuterium substitution strongly inhibits the metabolism of this compound by the cytochrome P450 enzyme system. Deuterated sevoflurane has the desirable anesthetic properties of sevoflurane, but undergoes considerably less metabolism and fluoride release. It may be particularly desirable for use as a long term conscious sedation agent.

Relevant Publications: Baker MT, Ronnenberg WC, Ruzicka JA, Chiang C-K, Tinker JH. Inhibitory effects of deuterium substitution on the metabolism of sevoflurane by the rat. Drug Metab Dispos, 1993:21;1170-1171.

INVENTORS

Max T. Baker, John H. Tinker

INTELLECTUAL PROPERTY STATUS

U.S. Patent No: 5,789,450

CONTACT INFORMATION

UIRF Ref. No: 96034

PROCESS FOR THE SYNTHESIS OF HEXAFLUOROISOPROPYL ETHERS

TECHNOLOGY REVIEW

This invention relates to a method of synthesizing hexafluoroisopropyl ether compounds from the reaction of methoxymalanonitrile with a bromine trifluoride composition.

INVENTORS

Max Baker, John Tinker and Jan Ruzicka

INTELLECTUAL PROPERTY STATUS

U.S. Patent 5,705,710

CONTACT INFORMATION

UIRF Ref. No: 97010

PROCESS FOR THE SYNTHESIS OF HEXAFLUOROPROPANES

TECHNOLOGY REVIEW

The invention relates to a method of synthesizing 1,1,1,3,3,3-hexafluoropropanes.

INVENTORS

Max Baker and Jan Ruzicka

INTELLECTUAL PROPERTY STATUS

U.S. Patent 5,789,630

CONTACT INFORMATION

UIRF Ref. No: 01020

BARDET-BIEDL SUSCEPTIBILITY GENE AND USES THEREOF

TECHNOLOGY REVIEW

A method of diagnosing Bardet-Biedl Syndrome comprising identification of a mutation in a NGVN polypeptide or nucleic acid. BBS is characterized by diverse symptoms such as obesity, diabetes, hypertension, mental retardation, renal cancer, retinopathy and hypogonadism. The human NGVN protein is 731 amino acids in length and coded for by a gene spanning 17 exons.

INVENTORS

Val C. Sheffield, Edwin Stone, and Darryl Nishimura

INTELLECTUAL PROPERTY STATUS

U.S. Patent 7,008,782 issued March 7, 2006

CONTACT INFORMATION

UIRF Ref. No: 07061

ZINC-FINGER NUCLEASE AND RNA INTERFERENCE MEDIATED INACTIVATION OF VIRAL GENOMES

TECHNOLOGY REVIEW

The present invention provides methods and compositions for targeted cleavage of viral genomes using recombinant zinc-finger proteins (ZFN), and target inactivation of viral gene expression using RNA interference. Specifically, the methods and compositions of the invention may be used to target viral hepatitis sequences.

INVENTORS

Anton P. McCaffrey and Thomas J. Cradick

INTELLECTUAL PROPERTY STATUS

Provisional Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 07040

METHOD OF MAKING CYCLIC POLYPEPTIDES WITH INTEINS

TECHNOLOGY REVIEW

The present invention describes biologic methods for producing and screening internally cyclized polypeptides and provides a biological platform for efficiently synthesizing internally cyclized polypeptides and for making a library of cyclic polypeptides that provides a high through-put method for screening biological activity.

The invention also describes cyclic peptides for use in treating Staphylococcal infections.

The methods described are both easier and cheaper than current chemical synthesis methods.

Relevant Publications: "Biosynthesis of Staphylococcus aureus autoinducing peptides using the Synechocystis DnaB mini-intein.", C. M. Malone, B. R. Boles and A. R. Horswill. 2007, Appl Environ Microbiol, 73;19:6036-6044.

INVENTORS

Alexander R. Horswill

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 07041

A ZEBRA FISH BASED SCREEN FOR AGENTS WITH ABILITY TO PREVENT CELL DEATH

TECHNOLOGY REVIEW

The present invention describes a zebrafish mutant useful for the screening of candidate therapeutics for the treatment of neurodegenerative diseases such as Parkinsons, Alzheimers, and amyotrophic lateral sclerosis (ALS). The invention further describes methods of screening candidate therapeutics to treat neurodegenerative diseases and diseases or disorders characterized by melanocyte cell death, using the zebrafish mutant, or other teleosts deficient in the same gene. Further, the invention provides methods for screening of candidate therapeutics for the treatment of melanomas. The invention provides targets and methods for the treatment of neurodegenerative diseases and melanomas.

Relevant Publication: McNeill, M. S., Paulsen, J., Bonde, G., Burnight, E., Hsu, M.-Y., and Cornell, R. A. (2007). Cell death of melanophores in zebrafish trpm7 mutant embryos depends on melanin synthesis. J. Investigative Dermatology (in press)

Elizondo, M. R., Arduini, B. L., Paulsen, J., MacDonald, E. L., Sabel, J. L., Henion, P. D., et al. (2005). Defective skeletogenesis with kidney stone formation in dwarf zebrafish mutant for trpm7. Curr Biol 15, 667-71.

Cornell, R. A., Yemm, E., Bonde, G., Li, W., d'Alencon, C., Wegman, L., et al. (2004). Touchtone promotes survival of embryonic melanophores in zebrafish. Mech Dev 121, 1365-76.

INVENTORS

Robert A. Cornell

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 07085

HALIDES IN THE TREATMENT OF PATHOGENIC INFECTION

TECHNOLOGY REVIEW

This technology consists of the re-introduction of a core substrate in the respiratory system's endogenous defense against infection enhancing mucosal antiviral immunity in the lung. This family of substrates is missing in CF patients because the substrates are typically supplied to the lung interior surface by the cystic fibrosis conductance regulator (CFTR), the channel that it inactivated by mutation in CF. When these substrates are re-introduced into the lungs, the endogenous host defense pathway is re-activated and that portion of host anti-viral and anti-microbial defenses becomes functional.

BENEFITS

• Simple treatment
• Cost effective
• Multi-spectrum protection
• Lower risk of side-effects
• Lower risk of reistance
• Can be used for treatment and prophylaxis

INVENTORS

Paul B. McCray, Jr., Botund Banfi, Anthony Fischer, Joseph Zabner

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 07015

METHODS AND COMPOSITIONS RELATED TO PLUNC RELATED SURFACTANT POLYPEPTIDES

TECHNOLOGY REVIEW

The present invention describes novel surfactant compositions and methods for lowering the surface tension of a liquid-air interface. The compositions comprise all or part of a polypeptide of the PLUNC family. Surfactants facilitate respiration by continually modifying the surface tension of the fluid normally present within the alveoli. Surfactants are necessary in order to keep airways open and able to absorb oxygen. Surfactants are generally useful in treating respiratory distress syndrome (RDS), acute respiratory distress syndrome (ARDS), and chronic obstructive pulmonary disease (COPD) in premature infants, The PLUNC proteins described in the invention may be produced recombinantly in E. coli or other suitable hosts and therefore could be used as a topical agent for respiratory, oral, and other applications.

INVENTORS

Paul B. McCray, Jr., Jennifer Bartlett, Lokesh Gakhar, Rama K. Mallampalli, and Subramanian Ramaswamy

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 05035

NOVEL SIALIC ACID PERMEASE OF HAEMOPHILUS INFLUENZAE

TECHNOLOGY REVIEW

Nontypeable Haemophilus influenzae is an opportunistic pathogen and a common cause of otitis media in children and of chronic bronchitis and pneumonia in patients with chronic obstructive pulmonary disease. H. influenzae utilizes sialic acid, a sugar readily available in the respiratory tract. This invention consists of a method to treat or prevent a Haemophilus influenzae infection by administering a sialic acid permease inhibitory agent in an amount that reduces the uptake of sialic acid by the bacterium. In the absence of sialic acid transporters siaP or siaT, H. influenzae cannot incorporate sialic acid into its lipooligosaccharides, making the organism unable to survive when exposed to human serum and causing reduced viability in biofilm growth. This technology also provides methods for determining both the inhibitory activity and binding activity of the sialic acid transporters. This invention may also be used to treat Haemophilus somnus, H. gallarium, Vibrio vulnificus, Vibrio cholera, Shigella flexneri, Pseudomonas aeruginosa, Helicobacter pylori, Pasturella multicidia, or Salmonella enteritidis.

Relevant Publications: Allen, Simon, Zaleski, Anthony, Johnston, Jason W., Gibson, Bradford W., and Apicella, Michael A., Novel Sialic Acid Transporter of Haemophilus influenzae, Infect. Immun., 73 (9): 5291-5300 2005.

INVENTORS

Michael A. Apicella, Simon Allen, Bradford W. Gibson, Anthony Zaleski

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application 11/331,735, PCT Patent Application PCT/US06/01108

CONTACT INFORMATION

UIRF Ref. No: 02051

MUTANT STRAIN OF NEISSERIA MENINGITIDIS (NMBAII K3) WHICH LACKS LIPOOLIGOSACCHARIDE (LOS) AND RMP PROTEIN

TECHNOLOGY REVIEW

Neisseria meningitidis is one of the major causative agents of bacterial meningitis and septicemia in children and young adults, with an estimated 500,000 cases and 50,000 deaths per year worldwide, a number that is frequently accentuated by epidemic outbreaks. The rapid progression of meningococcal disease makes proper diagnosis and subsequent treatment often vital to the survival of infected individuals. If not properly diagnosed and treated, meningococcal infections can lead to shock and death within a matter of hours. Better prevention, diagnosis and treatment of meningococcal infections are needed. This technology provides for a vaccine to protect against N. meningitidis colonization or infection. The vaccine contains an immunogenic amount of isolated and purified transgenic N. meningitidis cell in combination with a physiologically-acceptable, non-toxic vehicle. The purified cell contains a disrupted msbB gene, where the disruption results in altered acyltransferase activity, such that the cell has reduced lipooligosaccharide expression. Vaccines of this invention can also include effective amounts of immunological adjuvants, known to enhance an immune response.

Relevant Publications: Post, D.M., Ketterer, M.R., Phillips, N.J., Gibson, B.W., Apicella, M.A., The msbB mutant of Neisseria meningitidis strain NMB has a defect in lipooligosaccharide assembly and transport to the outer membrane, Infect. Immun., 71(2): 647-655 (2003).

INVENTORS

Michael A. Apicella, Deborah M. Post

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application 10/652,857

CONTACT INFORMATION

UIRF Ref. No: 01025

VACCINE AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF GONORRHEA

TECHNOLOGY REVIEW

Over 300,000 women per year contract gonorrhea in the U.S. Gonorrhea is a major cause of infertility and pelvic inflammatory disease, and is a major co-factor in the spread of HIV1. The sexually transmitted pathogen Neisseria gonorrhoeae, the causative agent in gonorrhea, discriminates between the sexes and uses different mechanisms to infect men than for infection of women. This invention discloses vaccines and chemotherapeutics to prevent and treat gonorrhea in women. The invention consists of various strains of gonococcal proteins released by the gonococcus bacteria. The genes of these proteins are present in gonococcal DNA and are vaccine candidates.

Relevant Publications: Edwards, J. L. and Apicella, M. A., Neisseria gonorrhoeae: The molecular mechanisms that initiate infection differ between men and women., Clin. Microbiol. Rev., 17 (4): 965-981 (2004).

Edwards, J. L., Entz, D.D. and Apicella, M. A., Gonococcal phospholipase d modulates the expression and function of complement receptor 3 in primary cervical epithelial cells, Infect. Immun.71(11):6381-91, (2003).

INVENTORS

Michael A. Apicella, Eric Brown, Jennifer Lynn Edwards, Bradford W. Gibson, and Karoline Scheffler

INTELLECTUAL PROPERTY STATUS

U.S. Patent Applications 10/665,990 and 10/066,551
Allowed Claims for U.S. Pat. App. 10/066,551 are directed to secreted p55 proteins from Neisseria gonorrhoeae that function in the modification of cell membrane enhancing bacterial entry. The claims also include compositions that include the p55 protein. Because the claims are directed to both compound and composition claims, the claims cover any use of the compound or composition, and are not limited to a specific use.
Allowed Claims for U.S. Pat. App. 10/665,990 are directed to Neisseria gonorrhoeae 1291 phospholipase D (PLD) polypeptide. The peptides may be conjugated or linked to another polypeptide or to a polysaccharide. The polypeptide may be in the form of a composition, such as in conjunction with an immunological adjuvant. Because the claims are directed to both compound and composition claims, the claims cover any use of the compound or composition, and are not limited to a specific use.

CONTACT INFORMATION

UIRF Ref. No: 03014

PHOTOCHEMICAL METHOD TO ELIMINATE OXYGEN INHIBITION OF FREE RADICAL POLYMERIZATIONS

TECHNOLOGY REVIEW

Current free radical polymerization methods are vulnerable to inhibition by oxygen. This oxygen inhibition reduces the polymerization rate, reduces the primary polymer chain length, and limits the ultimate attainable conversion in photopolymerization systems. This technology is a method for overcoming the oxygen inhibition of free radical polymerizations. The method involves a light-absorbing molecule interaction with oxygen to create singlet oxygen, and use of a compound which traps the singlet oxygen. This technology allows for either light-induced polymerizations or thermally-induced polymerizations, will allow for increased chain length of the primary polymer, provides a simplified process, and is much less expensive than inerting equipment. This technology can be applied to almost all industrial processes that involve free radical mechanism, including, but not limited to, coating and paint industries, adhesives, optics, dental filling, sealing compound, and stereo-lithography.

Relevant Publications: Gou, Lijing, Coretsopoulos, Chris N., Scranton, Alec B. Measurement of the dissolved oxygen concentration in acrylate monomers with a novel photochemical method. J. Polym. Sci., Part A: Polym. Chem., 42(5):1285-1292 (2004).

Gou, Lijing, Opheim, Blaine, Coretsopoulos, Chris N., Scranton, Alec B., Consumption of the Molecular Oxygen In Polymerization Systems Using Photosensitized Oxidation of Dimethylanthracene, Chem. Eng. Commun., 193(5):620-627 (2006)

INVENTORS

Alec Scranton, Lijing Gou

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application 10/752,778

CONTACT INFORMATION

UIRF Ref. No: 01055

CCT PROMOTERS TO ENHANCE PROTEIN EXPRESSION

TECHNOLOGY REVIEW

Two novel gene sequences, termed the CCTp208 and CCTp240 promoters, stimulate the expression of genes in a variety of cell types. Their activity is robust with several fold greater activity compared to existing viral promoters (e.g., SV40 promoter). The murine-based promoters are able to retain enhanced expression of desired genes in a stable fashion. The relatively small size of these mammalian sequences will permit easy packaging into adenoviral vectors for gene delivery. Because the promoters are not viral-based sequences, they circumvent effects of inflammatory host responses that turn off activity of commonly available promoters. These promoters can be used to generate recombinant proteins, and to express reporter genes in gene therapy and vaccine products.

INVENTORS

Rama K. Mallampalli

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed and PCT Application Filed

CONTACT INFORMATION

UIRF Ref. No: 05059

SYNTHESIS OF RACEMIC AND (s)-modafinil

TECHNOLOGY REVIEW

Modafinil is a psychostimulant agent that has gained much attention because of its recent approval by the FDA for the treatment of excessive daytime sleepiness. The agent has also received attention due to its low likelihood of potential for abuse. Recent work suggests that modafinil might also be of utility as a treatment of attention deficit/hyperactivity disorder (ADHD), Alzheimers disease, and in treating opioid-induced sedation.
This invention discloses the first asymmetric synthesis of (+)-(S)-modafinil. This is the first report of a biocatalytic one-flask oxidation/amidation utilizing a whole-cell transformation. The racemic synthesis of modafinil was accomplished in two steps, one chemical and one microbial transfromation. The enantioselective synthesis of (S)-modafinil was accomplished in just three steps, one chemical and two microbial transformations (60% overall yield). The new method provides a time savings and involves processes involving low environmental impact.

Relevant Publications: Olivo, H.F., Osrio-Lozada, A., and Peeples, Tonya L., Microbial Amidation/Oxidation of Benzhydrylsulfanyl Acetic Acid. Synthesis of (+)-Modafinil; Tetrahedron: Asymmetry 2005, 16, 3507-3511.

INVENTORS

Horacio F. Olivo

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 06029

SUPPRESSING POLYGLUTAMINE AGGREGATION AND TOXICITY

TECHNOLOGY REVIEW

The invention provides for methods of increasing the amount of C-terminal heat shock protein 70-interacting protein (CHIP) in a subject, as part of the treatment of Huntingtons disease and other neurodegenerative diseases, such as Alzheimers disease. The invention also provides for decreasing aggregation of, or increasing the solubility of polyglutamine proteins.

Relevant Publications: Miller, V.M., Nelson, R.F., Gouvion, C.M., Williams, A., Rodriguez-Lebron, E., Harper, S.Q., Davidson, B.L., Rebagliati, M.R., and Paulson, H.L., CHIP Suppresses Polyglutamine Aggregation and Toxicity In Vitro and In Vivo; J of Neuroscience; 2005; 25(40); 9152-9161.

INVENTORS

Henry Paulson and Victor Miller

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 06012

DIAGNOSIS AND TREATMENT OF BRAIN CANCER

TECHNOLOGY REVIEW

Certain embodiments of the present invention provide methods for determining the presence of a brain tumor or cancer and methods for predicting the recurrence of a brain tumor or cancer. The invention describes diagnosis methods, based on the detection of the silencing of a series of genes in the Wnt pathway, in a patient. The diagnostic methods described are for solid and childhood tumors, including specifically, medulloblastoma. Embodiments of the invention also include methods of treating patients having brain tumors or cancers, comprising the administration of specific nucleic acids. The methods described demonstrate that re-expression of certain, silenced genes, decrease cancer cell growth and increase cancer cell apoptosis.

INVENTORS

Rajeev Vibhakar, Beverly L. Davidson, and Anup Madan

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 06006

COMPOSITIONS FOR TREATING HEARING LOSS AND METHODS OF USE

TECHNOLOGY REVIEW

This invention includes compounds, compositions, and methods useful for modulating the expression and activity of genes involved in deafness caused, including mutations in GJB2, by dominant negative mechanism of action by RNA interference (RNAi) using small nucleic acid molecules. In one embodiment, the invention features one or more nucleic acid molecules and methods that independently or in combination modulate the expression of genes encoding proteins involved in deafness caused by dominant negative mechanism of action. The present invention provides a method of reducing the expression of GJB2 in a cell, which may decrease hearing loss.

Relevant Publication: Yukihide Maeda, Kunihiro Fukushima, Kazunori Nishizaki, and Richard J.H. Smith; In vitro and in vivo suppression of GJB2 expression by RNA interference; Human Molecular Genetics; 2005, 14, 12; 1641-1650

INVENTORS

Richard Smith

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 05064

VACCINE FORMULATIONS FOR LEISHMANIA

TECHNOLOGY REVIEW

This invention comprises a vaccine constructed from antigens found through screening a library of individuals with visceral leishmaniasis. The vaccine may comprise isolated or recombinant Leishmania protein as well as Leishmania DNA which codes for the applicable proteins. A particular delivery system for these antigens is an engineered avirulent recombinant strain of the bacterium Listeria monocytogenes. The present invention also includes methods of treating humans and animals with pharmaceutical compositions made using the Leishmania antigens.

INVENTORS

Mary Wilson, Daniella Martins, John Donelson, Selma Jeronimo, Kevin Bruhns, Noah Craft, and Jeffrey Miller

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application and Indian Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 05055

LECTIN BINDING TO CHOROIDAL NEOVASCULARIZATION

TECHNOLOGY REVIEW

The invention provides a method of identifying choroidal neovascularization (CNV) in a subject, comprising (a) contacting a Choroidal membrane and or Bruchs membrane of the subject with a lectin; (b) assessing the binding of said lectin to said Choroidal membrane and/or Bruchs membrane; and (c) comparing binding patterns of said lectins to the known structure of CNV. The invention further provides methods of diagnosing wet macular degeneration. The invention describes methods of targeting therapeutics to choroidal neovascularization.

INVENTORS

Robert Mullins

INTELLECTUAL PROPERTY STATUS

U.S. and International Patent Applications Filed

CONTACT INFORMATION

UIRF Ref. No: 05016

USE OF THE SODIUM IODINE SYMPORTER TO EFECT UPTAKE OF IODINE

TECHNOLOGY REVIEW

The invention includes methods for testing the ability of cells to take up and retain iodine. The invention describes methods for rendering a cell susceptible to iodine uptake and retention as part of the treatment of a variety of cancers. As a method of increasing iodine uptake and retention, the invention describes methods for decreasing the expression of the amino acid protein pendrin. The invention also includes methods of rendering a cancer cell, particularly head and neck squamous carcinoma cells, susceptible to radio-iodine therapy comprising introducing into the cell an expression construct encoding an iodide symporter.

Relevant Publications: Gaut, A., Niu, G, Krager, K, Graham, M., Trask, D., and Domann, F. Genetically Targeted Radiotherapy of Head and Neck Squamous Cell Carcinoma Using the Sodium-Iodide Symporter (NIS). Head and Neck, 26(3)2004, 265-271

INVENTORS

Frederick Domann, Andrew Gaut, Douglas Trask, Gang Niu, and Kimberly Krager

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 05014

OPIOID RECEPTOR LIGANDS AND METHODS FOR THEIR PREPARATION

TECHNOLOGY REVIEW

The invention provides novel compounds that are opioid receptor ligands. The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated with opioid receptor function by administering such compounds to a mammal in need of treatment. The invention also provides an improved method for isolating an intermediate compound useful for preparing the novel compounds.

INVENTORS

Thomas Prisinzano

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed and PCT Application Filed

CONTACT INFORMATION

UIRF Ref. No: 05005

COMPOSITIONS AND METHODS RELATED TO MODIFIED RETROVIRAL VECTORS

TECHNOLOGY REVIEW

The present invention provides a retrovirus virion pseudotyped with a Lymphocytic Choriomeningitis Virus (LCMV) envelope glycoprotein. The invention also describes a pseudotyped feline immunodeficiency virus (FIV) virion comprising an envelope glycoprotein from LCMV. The invention provides a method to pseudotype retroviruses to attain high titers suitable for ex vivo and in vivo gene transfer. The invention will be useful for gene therapy applications using retroviral vectors and provide a novel method for increasing the transduction efficiency and the targeting of specific cell types that were previously poorly accessible. In particular these methods may have applications for targeting tissues such as airway epithelia, cells of the CNS, hepatocytes and others. The methods may also facilitate the production of stable packaging cell lines for vector production.

Relevant Publication: Sinn PL, Burnight ER, Hickey MA, Blissard GW, McCray PB Jr. Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer. J Virol. 2005 Oct;79(20):12818-27.

INVENTORS

Paul B. McCray, Jr. Patrick L. Sinn, Dan Voytas and Junbiao Dai

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 05004

A BARDET-BIEDL SUSCEPTIBILITY GENE AND USES THEREOF

TECHNOLOGY REVIEW

The invention provides an isolated and purified nucleic acid encoding ADP-ribosylation factor-like 6, designated as BBS3. The invention further includes oligonucleotides and polypeptides comprising BBS3. The invention describes methods of diagnosing Bardet-Biedl Syndrome (BBS), a debilitating genetic disorder, based on mutations in BBS3. The invention further provides methods of identifying individuals genetically predisposed to BBS related maladies, including obesity, diabetes, renal defects, retinopathy, hydrogonadism, polydactyly, and or mental retardation.. The invention relates to specific sequences in Fibulin 1, 2, 4 and 5 and kits for detecting those sequences.

Relevant Publications: Chiang, A. P., Nishimura, D., Searby, C., Elbedour, K., Carmi, R., Ferguson, A.L., Secrist, J., Braun, T., Casavant, T., Stone, E. M., Sheffield, V. C. Comparative Genomic Analysis Identifies an ADP-Ribosylation Factor-like Gene as the Cause of Bardet-Biedl Syndrome (BBS3). American Journal of Human Genetics, 2004 Sep;75(3):475-84. Epub 2004 Jul 16.

INVENTORS

Edwin Stone, Val Sheffield, Thomas Casavant, Terry Braun, and Darryl Nishimura

INTELLECTUAL PROPERTY STATUS

U.S. and International Patent Applications Filed

CONTACT INFORMATION

UIRF Ref. No: 04051

METHODS AND COMPOSITIONS FOR SCREENING INVOLVING ENDOTHELIAL CELLS UNDER SHEARING CONDITIONS

TECHNOLOGY REVIEW

The present invention includes methods and compositions for screening endothelial cells under conditions that mimic physiological stress conditions. The invention provides methods for identifying or characterizing agents or pathways in endothelial cell function and processes of screening for candidate drugs to relieve oxidative stress in endothelial cells. Thus, the present invention has ramifications for the fields of cardiology, diabetes, and other areas involving endothelial cells under oxidative stress. The present invention further provides methods and compositions for evaluating candidate substances for their ability to modulate vascular endothelial cells in a relevant physiological context. Methods of the present invention include a method of identifying a protein involved in endothelial cell function.

The present invention also includes methods of for a candidate drug to relieve or reduce oxidative stress in an endothelial cell, and for treating chronic oxidative stress in an animal comprising administering to an endothelial cell in the animal an effective amount of an inhibitor of eNOS or nicotinamide adenine dinucleotide phosphate (NADPH).

INVENTORS

Khalid Kader and Christian H. Coyle

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed and PCT Application Filed

CONTACT INFORMATION

UIRF Ref. No: 04035

ALTERATIONS OF FIBULIN GENES IN MACULAR DEGENERATION

TECHNOLOGY REVIEW

The invention describes mutations in various fibulin genes that are predictive of and causative for macular degeneration. The invention further provides methods for detecting and treating specific age-related macular degeneration phenotypes. The invention relates to specific sequences in Fibulin 1, 2, 4 and 5 and kits for detecting those sequences.

Relevant Publications: Edwin M. Stone, Terry A. Braun, Stephen R. Russell, Markus H. Kuehn, Andrew J. Lotery, Paula A. Moore, Christopher G. Eastman, Thomas L. Casavant, and Val C. Sheffield. Missense Variations in the Fibulin 5 Gene in Association with Age-Related Macular Degeneration. NEJM, 351; 4, 20-27; 2004.

INVENTORS

Edwin Stone and Val Sheffield

INTELLECTUAL PROPERTY STATUS

U.S. and International Patent Applications Filed

CONTACT INFORMATION

UIRF Ref. No: 04033M

METHODS OF INHIBITING MANGANESE-CONTAINING SUPEROXIDE DISMUTASE 2 (MNSOD)

TECHNOLOGY REVIEW

The present invention provides RNA molecules (e.g., antisense, RNAi, or siRNA) specific for MnSOD, and further provides methods of reducing expression of MnSOD. Several RNA molecules have been identified that are specific for MnSOD and that can selectively reduce expression of MnSOD. The invention provides for such MnSOD RNA molecules, the DNA molecules encoding such RNA molecules, and also provides for methods of using the nucleic acid molecules of the invention to reduce the expression of MnSOD in a cell. A representative cell in which MnSOD expression can be reduced is a cancer cell. Such cancer cells can be epithelially-derived, and can include, for example, a head and neck cancer cell, a breast cancer cell, a colon cancer cell, and a prostate cancer cell.

INVENTORS

Douglas Trask andJonathan Bock

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed and PCT Application Filed

CONTACT INFORMATION

UIRF Ref. No: 04033V

METHODS OF INHIBITING VEGF-C

TECHNOLOGY REVIEW

The present invention provides RNA molecules (e.g., antisense, RNAi, or siRNA) specific for VEGF-C, and further provides methods of reducing expression of VEGF-C. Several RNA molecules have been identified that are specific for VEGF-C and that can selectively reduce expression of VEGF-C. The invention provides for such VEGF-C RNA molecules, the DNA molecules encoding such RNA molecules, and also provides for methods of using the nucleic acid molecules of the invention to reduce the expression of VEGF-C in a cell. A representative cell in which VEGF-C expression can be reduced is a cancer cell. Such cancer cells can be epithelially-derived, and can include, for example, a head and neck cancer cell, a breast cancer cell, a colon cancer cell, and a prostate cancer cell.

INVENTORS

Douglas Trask and Jonathan Bock

INTELLECTUAL PROPERTY STATUS

U.S. Patent 7,150,970 issued December 19, 2006

CONTACT INFORMATION

UIRF Ref. No: 04033C

METHODS OF INHIBITING COX-2

TECHNOLOGY REVIEW

The present invention provides RNA molecules (e.g., antisense, RNAi, or siRNA) specific for COX-2, and further provides methods of reducing expression of COX-2. Several RNA molecules have been identified that are specific for COX-2 and that can selectively reduce expression of COX-2. The invention provides for such COX-2 RNA molecules, the DNA molecules encoding such RNA molecules, and also provides for methods of using the nucleic acid molecules of the invention to reduce the expression of COX-2 in a cell. A representative cell in which COX-2 expression can be reduced is a cancer cell. Such cancer cells can be epithelially-derived, and can include, for example, a head and neck cancer cell, a breast cancer cell, a colon cancer cell, and a prostate cancer cell.

INVENTORS

Douglas Trask and Jonathan Bock

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed and PCT Application Filed

CONTACT INFORMATION

UIRF Ref. No: 04028

ANTIBODIES TO PHOSPHORYLATED TAU, METHODS OF MAKING AND METHODS OF USE

TECHNOLOGY REVIEW

The present invention provides a purified antibody that selectively binds to a human tau epitope comprising a phosphorylated tyrosine residue corresponding to the tyrosine residue.

INVENTORS

Gloria Lee

INTELLECTUAL PROPERTY STATUS

U.S. and PCT Patent Applications Filed and PCT Application Filed

CONTACT INFORMATION

UIRF Ref. No: 04007

RNA INTERFERENCE IN RESPIRATORY CELLS

TECHNOLOGY REVIEW

The present invention presents an RNAi molecule capable of mediating expression of a respiratory virus-specific messenger RNA in the respiratory epithelium, including tissues lining the sinuses, the nasal airways, the conducting airways and the alveolar epithelium, as a means to treat a variety of disorders. Specifically, methods and compositions are presented for the delivery of inhibitory nucleic acids to pulmonary epithelia. In certain embodiments of the present invention, the RNAi targets pro-inflammatory processes, viral pathogens, and other agents involved in airway diseases. Examples of such target diseases include asthma, cystic fibrosis, or interstitial lung disease.

INVENTORS

Paul McCray, Beverly Davidson, Anthony Fischer, Hong Peng Jia, Maureen Donovan, Patrick Sinn and Mark Behlke

INTELLECTUAL PROPERTY STATUS

U. S. Patent Application Filed and PCT Application Filed

CONTACT INFORMATION

UIRF Ref. No: 04002

GALLIUM INHIBITS BIOFILM FORMATION

TECHNOLOGY REVIEW

The present invention provides a gallium-containing composition for coating/impregnating a medical and/or industrial device or other device surface in order to prevent biofilm growth formation. The present invention also provides a method of preventing or inhibiting biofilm growth formation.

INVENTORS

Bradley E. Britigan and Pradeep Singh

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed and PCT Application Filed

CONTACT INFORMATION

UIRF Ref. No: 03075

METHOD AND KIT FOR IDENTIFYING VANCOMYCIN-RESISTANT ENTEROCOCCUS (VRE)

TECHNOLOGY REVIEW

The present invention relates to polynucleotide-based methods, compositions, kits and devices useful in the detection of the vanA and vanB genes. These genes are each associated with vancomycin resistance of microorganisms. The invention describes rapid real time PCR for the detection of both vanA and vanB positive enterococci, including novel primers and fluorescent probes specific for the vanA gene and all known vanB genes. The overall sensitivity and specificity of the described assay is 93.4% and 99.1%, respectively.

Relevant Publications: Dodgson, K. J., VRE Detection: A New Gold Standard, Clinical Microbiology Newsletter, 26:4, 25-30, 2004

INVENTORS

Kirsty Dodgson

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 03068

POLYSACCHARIDES AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION

TECHNOLOGY REVIEW

The present invention provides sulfo-protected polysaccharides and methods for preparing sulfo-protected polysaccharides, as well as intermediate compounds useful in such methods. In particular, the invention includes a method of protecting and deprotecting molecules with multiple hydroxyl functionalities or a combination of hydroxyl and amine functional groups using sulfo protecting groups. The sulfo protected monosaccharides of the invention can be used in glycolsylation reactions to form polysaccharides and can also be used as building blocks in the preparation of glycosaminoglycans, such as chondroitin sulfate.

INVENTORS

Robert Linhardt, Nathalie Karst, Tasneem Islam

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 03065

COMPOSITIONS AND METHODS RELATED TO A DIMERIC CLASS I AND II-LIKE MOLECULE (dsMHC I and dsMHC II)

TECHNOLOGY REVIEW

The present invention relates generally to the fields of medicine and immunology. More particularly, it concerns compositions and methods related to identification, modulation and/or abrogation of alloreactive T cells. Embodiments of the invention include dimeric soluble MHC molecules (dsMHCs) and compositions and methods for their use. The molecules may be used to downregulate activated T cells. The dsMHCs may be administered by intraperitoneal infusion into a tissue or an organ recipient. The administration of dsMHCs molecules may also be supplemented with immunosupressant to induce the engraftment of allografts. dsMHCs molecules may also be used for visualization of alloreactive T cells in various tissues or organs.

INVENTORS

Nicholas Zavazava and Martin Kroenke

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 05026

GB VIRUS C (HEPATITIS G VIRUS) NS5A PROTEIN FOR THE TREATMENT OF HIV

TECHNOLOGY REVIEW

The invention includes a composition comprising a GBV-C (Hepatitis G Virus) NS5A peptide or polypeptide. The invention describes methods to treat, inhibit or prevent HIV infection comprising administering a composition including the NS5A peptide or polypeptide. Embodiments of the invention include therapeutic and preventative compositions comprising a GBV-C NS5A peptide or polypeptide alone, or in combination with other compositions.

Relevant Publications: Xiang J, McLinden, J H, Chang Q, Kaufman TM, and Stapleton JT. An 85-aa segment of the GB virus type C NS5A phosphoprotein inhibits HIV-1 replication in CD4+ Jurkat T cells. 2006. PNAS 103, 42, 15570-15575.

Xiang J, Martinez-Smith C, Gale Jr. M, Chang Q, LaBrecque DR, Schmidt WN, Stapleton JT. GB Virus type C NS5A sequence polymorphisms: Association with interferon susceptibility and inhibition of PKR-mediated eIF-2a phosphorylation. In Press. J Interferon Cytokine Res, 2005

INVENTORS

Jack T. Stapleton, Jinhua Xiang, Qing Chang and James McLinden

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 03053

GB VIRUS C (HEPATITIS G VIRUS) FOR THE TREATMENT OF HIV

TECHNOLOGY REVIEW

The invention includes methods to treat, inhibit or prevent HIV infection. Embodiments of the invention include therapeutic and preventative compositions comprising a GBV-C polypeptide, antibody, or peptide binding agent, wherein the composition attenuates HIV infectivity. The invention describes a therapeutic use for antibodies and/or binding agents that bind GBV-C proteins, and antigens used for producing these antibodies or binding agents. In certain embodiments, an HIV vaccine composition includes peptides derived from GBV-C polypeptides.

Relevant Publication: McLinden, JH; Kaufman, TM; Xiang, J; Chang, Q; Klinzman, D; Engel, AM; Hess, G; Schmidt, U; Houghton, M; and Stapleton JT. Characterization of an Immunodominant Antigenic Site on GB Virus C Glycoprotein E2 That is Involved in Cell Binding. Journal of Virology. 80, 24:12131-12140, 2006

INVENTORS

Jack T. Stapleton, Jinhua Xiang and Donna Klinzman

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 03021

FULL-LENGTH GB VIRUS C (HEPATITIS G VIRUS) RNA TRANSCRIPTS ARE INFECTIOUS IN PRIMARY CD4 POSITIVE T CELLS AND METHODS OF TREATING HIV

TECHNOLOGY REVIEW

The present invention is directed to methods of preparing or producing an infectious GBV-C (Hepatitis C Virus). More particularly, it concerns an infectious clone of GBV-C, which can be used in treatment of other related hepatitis viruses infections and HIV, as well as broader uses in therapeutic and preventative therapies.
Relevant Publication: George S, Xiang J, Stapleton JT. Clinical isolates of GB virus type C vary in their ability to persist and replicate in peripheral blood mononuclear cell cultures. Virology. 316:191-201, 2003

INVENTORS

Jack Stapleton, Jinhua Xing and Sarah George

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 00046

FULL-LENGTH GB VIRUS C (HEPATITIS G VIRUS) RNA TRANSCRIPTS ARE INFECTIOUS IN PRIMARY CD4 POSITIVE T CELLS AND METHODS OF TREATING HIV

TECHNOLOGY REVIEW

GB virus C (GBV-C or hepatitis G virus) is a recently described flavivirus that frequently leads to chronic viremia in humans. Although associated with acute post-transfusion hepatitis, it is not clear if GBV-C is pathogenic for humans. A full-length cDNA was constructed from the plasma of a person with chronic GBV-C viremia. Peripheral blood mononuclear cells (PBMCs) transfected with full-length RNA transcripts from this GBV-C clone resulted in viral replication, demonstrating an isolated infectious GBV-C nucleic acid molecule. In addition to composition involving an isolated infectious GBV-C nucleic acid molecule, the present invention concerns methods of inhibiting and treating HIV infections.

Relevant Publication: Xiang J, Wuenschmann S, Diekema D, Klinzman DJ, Patrick KD, George SL, Stapleton JT. Effect of Co-Infection with GB Virus C on Survival Among Patients with HIV Infection. N.Engl.J.Med. 345:707-714, 2001.

INVENTORS

Jack Stapleton, Jinhua Xing, Sabina Wunschmann, and Warren Schmidt

INTELLECTUAL PROPERTY STATUS

U.S. Patent 6,870,043 Issued March 22, 2005

CONTACT INFORMATION

UIRF Ref. No: 03052

CHLORHEXIDINE COMPOSITIONS AND METHODS FOR THEIR SYNTHESIS AND USE

TECHNOLOGY REVIEW

The present invention relates to new methods for producing oral antibacterial compositions containing chlorhexidine. The present invention describes alcohol-free chlorhexidine compositions for oral use, which are less likely to cause discomfort and xerostomia in a patient. The invention also provides methods for making hydrocolloidal compositions including chlorhexidine and sweetening or flavoring agents, in which case, the additional agents do not reduce the antibacterial activity of the chlorhexidine.

The inventions described include better tasting and alcohol free chlorhexidine compositions. Such compositions may lead to increased usage and compliance among patients, particularly based on decreased irritation and improved flavoring.

INVENTORS

David Drake and Cindy Marek

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 03047

METHODS AND COMPOSITIOS RELATED TO HIGH-TITER PSEUDOTYPED RETROVIRUSES

TECHNOLOGY REVIEW

The invention includes methods and compositions for increasing the titer, altering the tropism, and/or increasing the stability of retroviral or other pseudotyped viral preparations. Certain embodiments of the invention include compositions and uses of the envelope glycoprotein from the Jaaksiekte sheep retrovirus (JSRV). High titer viral preparations of the invention may be used in various therapeutic methods and compositions including, but not limited to the delivery of therapeutic genes. The high titer viral compositions may be used in vitro, ex vivo and/or in vivo for the treatment of various disorders and conditions.

INVENTORS

Paul McCray, Patrick Sinn and Hung Fan

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 03025

TOTAL SYNTHESIS OF DAURICHROMENIC ACID (ANTI-HIV NATURAL PRODUCT)

TECHNOLOGY REVIEW

A new efficient synthesis was developed for benzo[b]pyrene (chromo-3-ones), which includes the potent anti-HIV natural product daurichromenic acid, as well as related compounds including intermediates useful for the synthesis of it. This method specifically prepares 2H-benzo[6]pyrans by microwave-assisted tandem aldol reaction of a phenolic enolate followed by intramolecular SN2 type cyclization to form the 2H-benzo[6]pyran core structure. These compounds provide a therapeutic or diagnostic method to inhibit HIV growth in vitro or in vivo. They can be combined with a pharmaceutically acceptable liquid or solid to treat human patients.

INVENTORS

Zhendong Jin and Ying Kang

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application filed

CONTACT INFORMATION

UIRF Ref. No: 03024

DNA-DEPENDENT MRI CONTRAST AGENTS

TECHNOLOGY REVIEW

The present invention provides a magnetic resonance imaging contrast agent including a synthetic peptide or polypeptide having domains that specifically bind nucleic acid and one or more domains that specifically bind a parmagnetic metal, wherein at least one domain that specifically binds the paramagnetic metal is between domains that specifically bind nucleic acid. The madnetic resonance imaging contract agent of the invention may translocate into cells, i.e., cross cell membranes and preferably localize in the nucleus. The synthetic peptide or polypeptide exploits the specificity achieved by DNA binding proteins to deliver a paramagnetic metal to a cell or tissue.

INVENTORS

Sonya Franklin

INTELLECTUAL PROPERTY STATUS

U.S. Application Filed

CONTACT INFORMATION

UIRF Ref. No: 02059

BARDET-BIEDL SUSCEPTIBILITY GENE AND USES THEREOF

TECHNOLOGY REVIEW

The invention relates the fields of genetics and molecular biology. In particular, the invention relates to the identification of a gene that is involved in Bardet-Biedl syndrome (BBS), designated here as BBS1. Defects in this gene are associated with a variety of clinical symptoms including diabetes, hypgonadism, high blood pressure, renal cancer and other defects, retinal degeneration, congenital heart defects, limn deformity or polydactyly, mental retardation and obesity. Also provided are methods of therapy and methods of screening for therapeutic compositions.

INVENTORS

Val C. Sheffield, Edwin Stone, Kirk Mykytyn, Darryl Nishimura, and Charles Searby

INTELLECTUAL PROPERTY STATUS

U.S. Patent 6,962,788 issued November 8, 2005

CONTACT INFORMATION

UIRF Ref. No: 02013

REGENERATED CELLULOSE AND OXIDIZED REGENERATED CELLULOSE MEMBRANES AS POTENTIAL BIODEGRADABLE SCAFFOLDS FOR DRUG DELIVERY AND TISSUE ENGINEERING

TECHNOLOGY REVIEW

The present invention describes the use of regenerated celluloses (RC) and oxidized regenerated celluloses (ORC) in the manufacture of scaffolds for drug delivery and tissue engineering. The RC and ORC are biodegradable and biocompatible. The carboxyl, aldehyde, or ketone groups present on the ORC scaffold serve as sites for cell, drug, protein and/or peptide attachment or further chemical modification to induce cell adhesion and subsequent proliferation. The method of manufacture of these membrane structures is simple, and produces flexible structures that maintain their strength when hydrated.

INVENTORS

Vijay Kumar

INTELLECTUAL PROPERTY STATUS

U.S. Patent No. 6,800,753 issued October 5, 2004 and PCT Applications Filed

CONTACT INFORMATION

UIRF Ref. No: 01049

GENE DISCOVERY FOR DETECTION AND AMELIORATION OF JUVENILE POLYPOSIS

TECHNOLOGY REVIEW

A new gene discovery may allow for earlier detection of carriers of juvenile polyposis (JP), and possibly help to prevent the development of associated cancers through improved screening of patients. JP is an autosomal dominant disease characterized by a predisposition to hamartomatous gastrointestinal polyps and gastrointestinal cancer. Germline mutations in the genes BMPR1A and SMAD4 have been demonstrated to be responsible for about 40% of JP cases, and the genetic basis of the remainder of the cases is unknown. This invention allows for the presymptomatic diagnosis of gene carriers, allowing for more careful screening of affected patients to prevent the development of gastrointestinal cancers, and reduction of endoscopic screening in non-carriers of the mutant gene.

INVENTORS

James Howe and Lauri Aaltonen

INTELLECTUAL PROPERTY STATUS

U.S. Patent No. 6,423,491 issued July 23, 2002

CONTACT INFORMATION

UIRF Ref. No: 01038

BARDET-BIEDL SUSCEPTIBILITY GENE AND USES THEREOF

TECHNOLOGY REVIEW

The invention relates the fields of genetics and molecular biology. In particular, the invention relates to the identification of a gene that is involved in Bardet-Biedl syndrome (BBS), designated here as BBS4. Defects in this gene are associated with a variety of clinical symptoms including diabetes, hypgonadism, high blood pressure, renal cancer and other defects, retinal degeneration, congenital heart defects, limn deformity or polydactyly, mental retardation and obesity. Also provided are methods of therapy and methods of screening for therapeutic compositions.

INVENTORS

Val C. Sheffield, Edwin Stone, Kirk Mykytyn

INTELLECTUAL PROPERTY STATUS

U.S. Patent 7,045,317 issued May 16, 2006

CONTACT INFORMATION

UIRF Ref. No: 99028

ALPHA HELICAL PEPTIDES WITH BROAD SPECTRUM ANTIMICROBIAL ACTIVITY THAT ARE INSENSITIVE TO SALT

TECHNOLOGY REVIEW

The present invention provides new methods, combined compositions, and kits for use in inhibiting microbial growth and proliferation, reducing resistance to antimicrobials, and providing novel antibiotics for treating disease. The peptides developed have broad spectrum antimicrobial activities and salt insensitivity and are useful alone or in combination with other agents or antimicrobials in treating cystic fibrosis or other respiratory system diseases. These peptides also have broad spectrum, antibacterial activity against Gram positive and Gram negative bacterial strains, including several multiply drug resistant strains.

INVENTORS

Brian Tack, Paul McCray, Michael Welsh, Sue Travis, Robert Lehrer

INTELLECTUAL PROPERTY STATUS

Applications Filed

CONTACT INFORMATION

UIRF Ref. No: 01024

NEW PROCESS FOR PREPARING SAPONIN COMPOUNDS

TECHNOLOGY REVIEW

A new process was developed for preparing saponin compounds. This new process can also provide for the preparation of compounds and intermediates leading thereto. The compounds are related to naturally occurring saponins such as OSW-1 (Ornithogalum saundersiae) and analogues that are very useful as anticancer drugs.

INVENTORS

Zhendong Jin and Wensheng Yu

INTELLECTUAL PROPERTY STATUS

Patent No. 6,753,414 issued June 22, 2004

CONTACT INFORMATION

UIRF Ref. No: 01016

NEW METHOD FOR REDUCING ANTIOXIDANT ENZYME LEVELS IN TUMOR CELLS USING ANTISENSE OLIGONUCLEOTIDES

TECHNOLOGY REVIEW

Antisense technology can be used to alter the expression of antioxidant enzymes, some of which protect cancer cells. This invention provides an antisense oligonucleotide that specifically binds to an antioxidant enzyme start codon so as to inhibit the level of antioxidant enzymes in the cell. This methodology can be used to treat an antioxidant enzyme malfunction disorder in a mammal by reducing the antioxidant enzyme levels in a cell, thus sensitizing it for various antitumor modalities. The antioxidant enzyme mRNA to which these oligonucleotides bind may be manganese superoxide dismutase, copper and zinc superoxide dismutase, catalase, phospholipid glutathione peroxidase, or cytosolic glutathione peroxidase.

INVENTORS

Larry Oberley, Christine Weydert and Benjamin Smith

INTELLECTUAL PROPERTY STATUS

Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 01007

NOVEL AUTOINDUCER MOLECULES AND USES THEREFOR

TECHNOLOGY REVIEW

The invention includes the discovery of a novel autoinducer molecule, Pseudomonas Quinoline Signal (PQS), which may lead to the development of antibiotics for the treatment of Pseudomonas aeruginosa infection. P aeruginosa is one of the most prevalent Gram negative bacterium found in patients with hospital-acquired bacterial infections (patients with AIDS, cancer, burns and Cystic Fibrosis are particularly susceptible to P aeruginosa). PQS functions in the intracellular signal molecule in the cell-to-cell communication system of P aeruginosa. The invention includes the PQS molecules, and their ability to regulate gene expression and activity in the LasR and/or Rh1R proteins.

Relevant Publication: Quinoline Signaling in the Cell-to-Cell Communication System of Pseudomonas aeruginosa, Everett Pesci, Jared Milbank, James Pearson, Susan McKnight, Andrew Kende, E. Pete Greenberg and Barbara Iglewski, PNAS, 1999, Vol. 96, 11229-11234.

INVENTORS

E. Pete Greenberg, Barbara Iglewski, Andrew Kende, Jared Milbank, James Pearson, Everett Pesci

INTELLECTUAL PROPERTY STATUS

Patent Application Filed

CONTACT INFORMATION

UIRF Ref. No: 00066

S-METHYLCYSTEINE, S-ETHYLCYSTEINE AND RELATED S-ALKYLTHIOLS AS ANTAGONISTS TO THE EFFECTS OFS-NITROSOTHIOLS AND NITRIC OXIDE

TECHNOLOGY REVIEW

The invention describes methods of inhibiting the actions of S-nitrosothiols and nitric oxide which often occur in conditions such as septic shock, chronic or acute pain syndromes, uterine hypotonus, or certain gastrointestinal disorders. The method involving inhibiting the cellular binding of s-nitrosothiols to their cellular receptors or the signal transduction that would result. This is accomplished by administering an S-alkylthiol such as S-methyl-L-cysteine or S-ethyl-L-cysteine to a patient as an antagonist of S-nitrosothiol.

INVENTORS

James N. Bates and Stephen Lewis

INTELLECTUAL PROPERTY STATUS

U.S. Patent 7,226,766 issued June 5, 2007

CONTACT INFORMATION

UIRF Ref. No: 00057

METHODS TO PREPARE AND USE EPIDERMAL STEM CELLS

TECHNOLOGY REVIEW

The invention describes a method to prepare epidermal stem cells, which are undifferentiated self-renewing cells. The method comprises separating a population of mammalian epidermal cells comprising epidermal stem cells into a substantially pure population of epidermal stem cells and, preferably, at least one population of cells that does not comprise a substantial portion, e.g., less than a detectable amount, of epidermal stem cells. The invention also provides for epidermal stem cells and methods of using epidermal stem cells, e.g., for cell based therapies.

INVENTORS

Jackie R. Bickenbach and Martine Dunnwald

INTELLECTUAL PROPERTY STATUS

Patent No. 6,927,060 issued August 9, 2005

CONTACT INFORMATION

UIRF Ref. No: 00052

NEW GENE THERAPY FOR CANCER UTILIZING Ad-TRAIL

TECHNOLOGY REVIEW

This new gene therapy method describes the production of an adenovirus engineered to encode the gene for human TRAIL (Ad-TRAIL). TRAIL (TNF-related apoptosis-inducing ligand) is a member of the TNF (tumor necrosis factor) superfamily of cytokines that induces apoptosis in a variety to cancer cells, but not to normal cells and tissues. Introduction of the human TRAIL gene into TRAIL-sensitive tumor cell targets using Ad-TRAIL leads to the rapid production and expression of the TRAIL protein, and subsequent apoptotic death of the tumor cells. The generation of Ad-TRAIL is a novel method of using TRAIL as an anti-tumor therapeutic, and suggests the potential use for an adenovirus encoding TRAIL as a method of gene therapy for numerous cancer types in vivo. It is anticipated that Ad-TRAIL could be used as a treatment for many types of solid tumors, such as breast, prostate, bladder, melanoma and colon.

INVENTORS

Tom Griffith and Tim Ratliff

INTELLECTUAL PROPERTY STATUS

Patent No. 6,900,185 issued May 31, 2005

CONTACT INFORMATION

UIRF Ref. No: 00031

POWDERED/MICROFRIBRILLATED OXIDIZED CELLULOSE

TECHNOLOGY REVIEW

This invention relates to the preparation of a cellulose excipient for use in the food, pharmaceutical, cosmetic and agricultural fields. The new material serves as a binder, filler, and/or disintegrant in the design and development of a solid dosage form. It can be readily converted into an aqueous dispersion for use in topical formulations and in a bead form use in drug delivery and related applications. Further, the material may also be used as a suspending agent. Another advantage of this material is that it is cost effective and can be manufactured to comply with the existing USP specifications for microcrystalline cellulose.

INVENTORS

Vijay Kumar

INTELLECTUAL PROPERTY STATUS

Patent 6,821,531 issued November 23, 2004

CONTACT INFORMATION

UIRF Ref. No: 00027

BIODEGRADEABLE OXIDIZED CELLULOSE ESTERS

TECHNOLOGY REVIEW

The present invention relates to the preparation of a series of oxidized cellulose esters suitable for use as a drug carrier in the development of biodegradable controlled and/or sustained release pharmaceutical, agricultural, and veterinary compositions, such as films, compacts, microspheres, and pellets. The esters are prepared by acylation of oxidized cellulose having at least 3% carboxyl groups. The resulting oxidized cellulose esters are soluble in aqueous alkaline solutions, water, and a variety of organic solvents.

INVENTORS

Vijay Kumar; Yang Dong

INTELLECTUAL PROPERTY STATUS

U.S. Patent Application Pending
U.S. Publication No. 2002/0086990

CONTACT INFORMATION

UIRF Ref. No: 00022

POWDERED OXIDIZED CELLULOSE

TECHNOLOGY REVIEW

This invention relates to the development of a new method to produce oxidized cellulose in high yields and different levels of oxidation. Oxidized cellulose is a biodegradeable, biocompatible polymer commonly used to stop bleeding during surgery and to prevent the formation of adhesions following surgery. The present invention allows the preparation of microparticles and aqueous dispersions of oxidized cellulose suitable for use in pharmaceutics as an immobilizing matrix for a variety of drugs, chemicals and biological macromolecules. Additional uses of the technology include; the development of implantable biomaterials and implantable/injectable drug delivery systems.

INVENTORS

Vijay Kumar

INTELLECTUAL PROPERTY STATUS

U.S. Patent 6,627,749 Issued September 30, 2003

CONTACT INFORMATION

UIRF Ref. No: 00015

RAPID GENERATION OF RECOMBINANT ADENOVIRAL VECTORS

TECHNOLOGY REVIEW

The present invention describes a novel adenovirus backbone plasmid, which when co-transfected with a shuttle vector, is useful for rapid production of recombinant viruses. The invention also provides host cells and a cloning system for generating recombinant adenoviruses. The recombinant viruses may be useful as research tools and for use in therapeutic gene therapy.

Relevant Publication: A simple method for the rapid generation of recombinant adenovirus vectors, RD Anderson, RE Haskell, H Xia, BJ Roessler and BL Davidson, Gene Therapy, 2000, 7, 1034-1038.

INVENTORS

Richard Anderson, Beverly L. Davidson, Ronald Haskell, and Haibin Xia

INTELLECTUAL PROPERTY STATUS

Patent 6,830,920 December 12, 2004

CONTACT INFORMATION

UIRF Ref. No: 00011

VARIANT VARICELLA-ZOSTER VIRUSES AND METHODS OF USE

TECHNOLOGY REVIEW

This invention describes a new isolate of VZV which has lost an antigenic site on one of its surface proteins and which includes several, previously unreported gene sequences. The invention also provides a method for producing a modified attenuated VZV and is directed to a vaccine composition that includes a modified attenuated Varicella Zoster virus. The invention provides a method for detecting antibodies that specifically bind to a Varicella Zoster polypeptide and describes kits for detecting antibodies that specifically bind to a Varicella Zoster peptide. This invention provides a method for detecting the presence of a Varicella Zoster virus in an animal and also describes a method for diagnosing a disease, for instance chicken pox and shingles, caused by VZV.

Relevant Publication : Antigenic Variation of Varicella Zoster Fc Receptor gE: Loss of a Major B Cell Epitope in the Ectodomain, Richard A. Santos, Jorge A. Padilla, Christopher Hatfield and Charles Grose, Virology, 1998, 49, 21-31.

INVENTORS

Charles Grose and Richard Santos

INTELLECTUAL PROPERTY STATUS

Patent No. 6,528,066 issued March 4, 2003
Divisional Application Filed

CONTACT INFORMATION

UIRF Ref. No: 98079

THERAPEUTICS AND DIAGNOSTICS FOR OCULAR ABNORMALITIES

TECHNOLOGY REVIEW

Methods and compositions for treating ocular disorders such as retinal detachment and macular degeneration and methods and compositions for prognosing or diagnosing retinal detachment or macular degeneration in a subject are disclosed. In one aspect, the invention provides isolated or recombinant IPMC (interphotoreceptor matrix (IPM)) polynucleotides. (IPM) is an extracellular matrix comprised of an array of proteins, glycoproteins, and proteoglycans, occupying the space between the apical surfaces of the neural retina and the RPE (retinal pigment epithelium). Discovery of novel IPM components allows identification of novel therapeutic and diagnostic agents for diseases or conditions associated with abnormal IPM, such as retinal detachment, chorioretinal degenerations, retinal degenerations and macular degenerations such as AMD, or other dystrophies or degenerations involving IPM, cones or rods.

In still another aspect, the invention provides methods for treating or preventing the development of a disease or condition in a subject by administering to the subject an effective amount of an IPMC therapeutic. In some methods, the disease or condition to be treated is photoreceptor death. In other methods, the disease or condition to be treated is retinal detachment. In some methods, the IPMC therapeutic administered is a IPMC polynucleotide. In some methods, the IPMC therapeutic administered is a IPMC polypeptide. In some methods, the IPMC therapeutic is an antibody that specifically binds to an IPMC polypeptide. The present invention further provides methods for identifying a compound capable of modulating IPMC gene expression in a cell.

INVENTORS

Gregory Hageman and Markus Kuehn

INTELLECTUAL PROPERTY STATUS

US patent # 7,312,050, issued 12/25/07

CONTACT INFORMATION

UIRF Ref. No: 99059

DIAGNOSTICS AND THERAPEUTICS FOR ARTERIAL WALL DISRUPTIVE DISORDERS

TECHNOLOGY REVIEW

The invention provides diagnostics, therapeutics and drug screening assays for arterial wall disruptive disorders, based on the discovery of a high level of correlation between the incidence of arterial wall disruptive disorders and the incidence of Age Related Macular Degeneration (AMD). In one aspect of the invention, the arterial wall disruptive disorder is an aortic aneurysm (AAA). The invention relates to the discovery that the incidence of an arterial wall disruptive disorders, including but not limited to aortic aneurysm, intra-cranial aneurysm, abdominal aortic aneurysm, and thoracic aortic aneurysm, in a subject correlates with the incidence of AMD. The present invention therefore provides a novel method for diagnosing arterial wall disruptive disorders or a predisposition to developing arterial wall disruptive disorders, methods for treating or preventing the development of arterial wall disruptive disorders in a subject, by administering to the subject, a pharmaceutically effective amount of a macular degeneration therapeutic, and in vitro and in vivo assays for screening test compounds to identify arterial wall disruptive disorder therapeutics.

INVENTORS

Gregory Hageman

INTELLECTUAL PROPERTY STATUS

U.S. and International Patent Applications Filed

CONTACT INFORMATION

UIRF Ref. No: 99031

DIAGNOSTICS AND THERAPEUTICS FOR MACULAR DEGENERATION

TECHNOLOGY REVIEW

The invention provides diagnostics, therapeutics and drug screening assays for Age Related Macular Degeneration (AMD) based on the discovery of a high level of correlation between the incidence of abdominal aortic aneurysm (AAA) and the incidence of AMD. The present invention therefore provides a novel method for diagnosing AMD, methods for treating or preventing the development of AMD in a subject, and in vitro and in vivo assays for screening test compounds to identify and treat AMD.

INVENTORS

Gregory Hageman

INTELLECTUAL PROPERTY STATUS

U.S. and International Patent Applications Filed

CONTACT INFORMATION

UIRF Ref. No: 99039

METHOD FOR INHIBITING INFLAMMATORY RESPONSES, INCLUDING ASTHMA

TECHNOLOGY REVIEW

This invention provides for treating at least one symptom of an inflammatory response in a mammal by administering a polypeptide to the mammal. The polypeptide can be a microbial polypeptide or a Mycobacterial polypeptide. It further provides an inflammation reaction inhibiting composition that includes a microbial polypeptide and a pharmaceutically acceptable carrier. The polypeptide can be administered prior to exposure to at least one suspected or known inflammation response-inducing agent, or administered during or after exposure to at least one suspected or known inflammation response-inducing agent.

INVENTORS

Timothy Ratliff and Joel Kline

INTELLECTUAL PROPERTY STATUS

Patent No. 6,638,518 issued October 28, 2003

CONTACT INFORMATION

UIRF Ref. No: 99038

MACULAR DEGENERATION DIAGNOSTICS AND THERAPEUTICS

TECHNOLOGY REVIEW

In one aspect the invention features methods for diagnosing a subject with macular degeneration or with a predisposition for developing macular degeneration. In a preferred embodiment, the diagnostic methods utilize a set of primers and/or probes for amplifying and/or detecting regions of the macular degeneration causing gene, and means for analyzing the macular degeneration causing gene for differences (mutations) from the normal coding sequence. For example, the MD causative mutation can be detected by